Paper Details

  1. Home
  2. Paper Details

Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment.

Author: CowanJ O, FlanneryE M, HancoxR J, HerbisonG P, McLachlanC R, TaylorD R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Regular terbutaline treatment in asthma was found to lead to a temporary increase in morning peak flows and a greater than expected rise in evening peak flows for the first 2 days of treatment, suggesting the development of tolerance to the bronchodilator effect of terbutaline.
Paper Details　
Original Abstract of the Article :
There is uncertainty about the development of airway tolerance to beta-agonists and the phenomenon of rebound bronchoconstriction on beta-agonist withdrawal. We have recently completed a study of the regular terbutaline and budesonide treatment in asthma. We report our observations on the effect of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/rmed.2000.0820

データ提供：米国国立医学図書館（NLM）

The Intricate Dance of Bronchodilator Tolerance and Rebound Bronchoconstriction

Inhaled beta-agonists are widely used to treat asthma, but their long-term use can lead to tolerance and rebound bronchoconstriction. This research explores the phenomenon of tolerance and rebound bronchoconstriction by examining the effects of regular inhaled terbutaline treatment in patients with asthma. The study employed a randomized, double-dummy, cross-over design to compare the effects of terbutaline, budesonide, combined treatment, and placebo.

Tolerance and Rebound: A Balancing Act

The study found that while terbutaline initially improved peak flows, tolerance developed over time, leading to a decrease in effectiveness. Additionally, the study observed rebound bronchoconstriction upon withdrawal of terbutaline, highlighting the potential for deterioration in asthma control. The study suggests that the development of tolerance and rebound bronchoconstriction might be mediated by downregulation of beta-receptors during treatment.

Navigating the Desert of Asthma Treatment

The study's findings underscore the importance of careful monitoring and management of inhaled beta-agonist treatment in asthma. It emphasizes the need for individualized treatment plans that consider the potential for tolerance and rebound effects. Just as a desert traveler needs to adapt to changing weather conditions, asthma patients need to adjust their treatment strategies as their bodies respond to medication.

Dr. Camel's Conclusion

This study provides valuable insights into the complex interplay between bronchodilator tolerance and rebound bronchoconstriction in asthma. The research highlights the need for a balanced approach to inhaled beta-agonist treatment, ensuring that patients receive optimal care while minimizing the risk of adverse effects. It's like navigating a desert, where a traveler needs to be aware of the potential for mirages and hidden dangers.

Date :
  1. Date Completed 2000-09-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

10955752

DOI: Digital Object Identifier

10.1053/rmed.2000.0820

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.